AS
CRSP icon

Altshuler Shaham’s CRISPR Therapeutics CRSP Stock Holding History

Altshuler Shaham’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$16.2K – 332
2024
Q4 		$16.2K Buy
+10
New +$472 ﹤0.01% 252

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Altshuler Shaham's CRSP Position: Q1 2026 in Review

Altshuler Shaham increased its CRISPR Therapeutics (CRSP) stake by 19% in Q1 2026, buying an estimated $4.22K and bringing the position to 500 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #231.

Altshuler Shaham first reported a position in CRSP in Q1 2021 and has held it in 7 quarters since. The position peaked at $122K in Q1 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Altshuler Shaham held 500 shares of CRISPR Therapeutics worth $23.8K as of Q1 2026.
  • Altshuler Shaham bought 80 CRISPR Therapeutics shares in Q1 2026, an estimated $4.22K.
  • CRISPR Therapeutics made up ﹤0.01% of Altshuler Shaham's portfolio in Q1 2026, its #231 holding.
  • Altshuler Shaham first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • Altshuler Shaham's CRISPR Therapeutics position peaked at $122K in Q1 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Altshuler Shaham's 13F filing for Q1 2026, filed 18 May 2026.